Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 52

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 52
---
3) months thereafter to seek Warrant Stockholder Approval until the earlier of the date Warrant Stockholder Approval is obtained or the May 2025 Warrants are no longer outstanding. “ Warrant Stockholder Approval” means approval from our stockholders of (i) the Anti-Dilution Adjustment (the approval sought by this Proposal No. 6) and (ii) an increase in the number of authorized shares of Common Stock to 350,000,000 shares of Common Stock under the Company’s Certificate of Incorporation (the approval sought by Proposal No. 5).

The May 2025 Warrants have an initial exercise price of $0.352 per share (110% of the combined public offering price per share of Common Stock and accompanying May 2025 Warrant). In addition to the Anti-Dilution Adjustment, which is subject to the approval of this Proposal No. 6, the number of May 2025 Warrant Shares issuable upon exercise of the May 2025 Warrants are subject to an additional adjustment, which is not subject to stockholder approval, in the event we effect a reverse stock split prior to the expiration of the May 2025 Warrants. If we effect a reverse stock split while the May 2025 Warrants are outstanding, the number of May 2025 Warrant Shares issuable upon exercise of the May 2025 Warrants will increase by 30% (the “ Reverse Stock Split Adjustment”). The May 2025 Warrants are immediately exercisable, except that the issuance of shares of Common Stock upon exercise of the May 2025 Warrants pursuant to the Anti-Dilution Adjustment is subject to Warrant Stockholder Approval. The May 2025 Warrants expire on the five-year anniversary of the later of the date that the Company files a Current Report on Form 8-K giving public notice of the Warrant Stockholder Approval (the “ Stockholder Approval Notice Date”) and the effective date of the filing of a certificate of amendment to our Certificate of Incorporation to increase our authorized number of shares of Common Stock to 350,000,000 shares.

We agreed not to consummate a Dilutive Issuance until the earlier of (i) eight months from the closing date of the Public Offering; and (ii) later of (a) the filing of a registration statement registering certain shares of Common Stock issuable as a result of the Anti-Dilution Adjustment, (b) the Stockholder Approval Notice Date, and (c) the effective